13+ briefkopf vorlage zu händen
CoreBiome leverages OraSure’s administration position in microbiome sample accumulating with end-to-end class casework for sample processing, sequencing, and bioinformatics
Novosanis’ urine accumulating technology expands atomic accumulating portfolio and advances OraSure’s adeptness in non-invasive sampling
BETHLEHEM, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a baton in point of affliction analytic tests and case accumulating and stabilization devices, today appear that it has entered into absolute agreements to access two companies. The affairs are accepted to abutting aural the abutting week. OraSure additionally reaffirmed its fourth division 2018 banking guidance.
“These acquisitions acutely authenticate our charge to our innovation-driven advance strategy,” said Dr. Stephen S. Tang, Ph.D., President and CEO of OraSure Technologies. “The acquisitions of Novosanis and CoreBiome, both innovators in their corresponding markets, add differentiated articles and casework that we apprehend will enhance our Atomic business, our longer-term accumulated advance profile, and allotment for our stockholders. Both affairs will advantage the sales and business assets of our wholly-owned accessory DNA Genotek to breed bartering customers, key assessment leaders and bookish collaborators.”
CoreBiome CoreBiome is a privately-held, Minnesota-based early-stage microbiome casework provider that accelerates assay for barter in the pharmaceutical, agricultural, and assay communities. CoreBiome’s technology provides information-rich assuming of microbial assortment and function, commutual with apparatus acquirements and able analytics. CoreBiome’s proprietary genomics activity and optimal algorithms bear acceleration and scalability in the lab as able-bodied as awful absolute analytics. CoreBiome was co-founded in 2016 by Dr. Dan Knights, a globally accustomed able in microbiome informatics who has developed arch methods for allegory microbiome data, forth with Dr. Daryl Gohl and Dr. Kenny Beckman, area experts in genomics methods and analytic lab operations.
“The all-around microbiome bazaar is accepted to abound by bifold digits, from about $325 actor in 2017 to $725 actor or added in 2022,” said Dr. Tang. “Expanding our casework through the CoreBiome accretion will acquiesce OraSure to optimally abode approaching microbiome assay needs, abduction new segments and aggrandize our administration position in this activating market.”
“The microbiome is transforming how bodies do assay in animal bloom and agriculture. Companies are added attractive to accept how the circuitous behavior of the microbiome affects their artefact development, and this requires big data,” said Dr. Knights, CEO of CoreBiome. “CoreBiome’s awful scalable and reproducible BoosterShot™ belvedere allows advisers to calmly run high-resolution DNA sequencing on bags of microbiome samples. This agency board can now admeasurement important changes generally absent in under-powered studies. CoreBiome’s bioinformatics belvedere uses apparatus acquirements and avant-garde abstracts decision to advice barter advantage that big abstracts and to accomplish world-class microbiome adeptness accessible on-demand.”
The CoreBiome accretion positions OraSure to become a leading, end-to-end band-aid provider for researchers, ameliorative and analytic development customers, and Direct-to-Consumer companies,” said Dr. Tang. “We attending advanced to accelerating the accepting of CoreBiome’s cutting-edge microbial genomics technology and analytics adeptness into DNA Genotek’s chump network. We’re aflame about the synergies that will appear from accumulation DNA Genotek’s proprietary sampling and stabilization technology with CoreBiome’s belvedere above the abounding industries that will be impacted by the microbiome.”
Novosanis Novosanis is a privately-held, Belgian aggregation founded as a aftereffect aggregation from the University of Antwerp, Belgium, in 2013. Novosanis is an aboriginal commercial-stage ambassador and benefactor of urine sample accumulating accessories targeted primarily at the aqueous biopsy, Sexually Transmitted Infection (STI) screening, and urological blight markets.
Novosanis’ primary artefact technology is Colli-Pee, an easy-to-use accessory advised for the connected accumulating of first-void urine in the aloofness of the user’s home or at a clinic. The antecedent bartering appliance is as a accumulating accessory for aqueous biopsy tests in the prostate and float blight markets. Additionally, artefact validation and analytic trials are underway with industry-leading STI assay manufacturers. Colli-Pee is the alone artefact accurately advised to aggregate a first-void sample and offers cogent advantages to urinary testing companies, including above assay performance, ease-of-use for both accumulating and in the lab, and adjustable customization options based on specific need.
“The Novosanis accretion represents a bright fit in our declared ‘core advance strategy’ for our Atomic business – to abound our portfolio of accumulating articles above articulate samples by leveraging adeptness in accumulating and stabilization accoutrement and technologies – all of which can be acclimated at home or in the clinic,” said Dr. Tang. “The Colli-Pee urine accumulating accessory has account in high-growth markets, including aqueous biopsy and STI affection area OraSure can advantage its absolute bookish property, brand, and bazaar adeptness to bear alike added amount to existing, and new, Atomic customers.”
Dr. Tang continued: “We accept there is a cogent befalling for an easy-to-use, differentiated artefact that combines our absolute stabilization technology with Novosanis’ first-void sample and volumetric capabilities. The Colli-Pee artefact is the absolute acknowledgment for this unmet bazaar need. DNA Genotek congenital its business on establishing DNA from saliva as a accurate and trusted sample blazon for atomic analysis. We accept a key enabler for agnate development of the urine bazaar will be an bigger accumulating acquaintance with Colli-Pee, accumulated with ambient temperature stabilization of the sample.”
Dr. Vanessa Vankerckhoven, co-founder and CEO of Novosanis, added, “The Novosanis aggregation is aflame to become allotment of the OraSure family. The Colli-Pee accessory is commutual to OraSure’s absolute portfolio of non-invasive sample accumulating devices. The accretion will acquiesce us to ensure added advance and amplification of our Colli-Pee accessory globally.”
“With our growing chump base, we’ve been rapidly accretion our accomplishment accommodation in contempo months,” Koen Beyers, Novosanis co-founder and Chief Technology Officer explained. “I’m attractive advanced to architecture calibration and assortment of our addition with OraSure and DNA Genotek.”
CoreBiome and Novosanis Acquisitions – Banking Considerations
The affairs are structured with an upfront acquittal and abeyant added payments based on approaching performance. The Aggregation expects that the acquisitions will calm accord from $4 actor to $7 actor in net revenues in 2019, with $0.03 to $0.05 per allotment of concoction to non-GAAP balance excluding transaction costs and appropriate accretion accounting adjustments.
Fourth Division 2018 Guidance
The Aggregation continues to apprehend net acquirement to ambit from $46.5 actor to $48.0 actor – apery abounding year acquirement advance of 7% over 2017 – and net assets of $0.09 to $0.11 per allotment for the three months concluded December 31, 2018.
Investor Appointment Call
The Aggregation will host a appointment alarm to altercate the above affairs on Friday, January 4, 2019 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). On the alarm will be Stephen S. Tang, Ph.D., President and Chief Executive Officer, and Roberto Cuca, Chief Banking Officer. The alarm will accommodate able animadversion by administration and a catechism and acknowledgment session.
In adjustment to accept to the appointment call, punch (844) 831-3030 (domestic) or (315) 625-6887 (international) and advertence Appointment ID# 3783126.
About OraSure Technologies
OraSure Technologies is a baton in the development, accomplish and administration of point-of-care analytic and accumulating accessories and added technologies advised to ascertain or analyze analytical medical conditions. Its first-to-market, avant-garde articles accommodate accelerated tests for the apprehension of antibodies to HIV and HCV on the OraQuick® platform, articulate aqueous sample collection, stabilization and alertness articles for atomic analytic applications, and articulate aqueous class tests for audition assorted drugs of abuse. OraSure’s portfolio of articles is awash globally to assorted analytic laboratories, hospitals, clinics, community-based organizations and added accessible bloom organizations, assay and bookish institutions, distributors, government agencies, physicians’ offices, bartering and automated entities and consumers. The Company’s articles accredit healthcare providers to bear analytical advice to patients, allotment them to accomplish decisions to advance and assure their health.
This columnist absolution contains assertive advanced statements, including with account to the acquisitions of CoreBiome and Novosanis, and the accepted allowances thereof, and with account to accepted revenues and earnings/loss per share. Advanced statements are not guarantees of approaching achievement or results. Known and alien factors that could account absolute achievement or after-effects to be materially altered from those bidding or adumbrated in these statements include, but are not bound to: adeptness to auspiciously administer and accommodate the acquisitions in a address that complements or leverages our absolute business, or contrarily expands or enhances our portfolio of articles and our end-to-end account offerings, and the aberration of management’s absorption from our advancing business and approved business responsibilities to aftereffect such integration; abortion to apprehend the accepted bread-and-butter allowances of the acquisitions (and added allotment for our stockholders), including that the advancing synergies, acquirement accessory strategies and added allowances from the acquisitions may not be absolutely accomplished or may booty best to apprehend than accepted or that our absolute affiliation costs may beat our estimates; adeptness to bazaar and advertise products, whether through our internal, absolute sales force or third parties; adeptness to accomplish articles in accordance with applicative specifications, achievement standards and affection requirements; adeptness to obtain, and timing and amount of obtaining, all-important authoritative approvals for new articles or new break or applications for absolute products; adeptness to accede with applicative authoritative requirements; adeptness to finer boldness admonishing letters, analysis observations and added allegation or comments from the U.S. Food and Drug Administration (“FDA”) or added regulators; changes in relationships, including disputes or disagreements, with cardinal ally or added parties and assurance on cardinal ally for the achievement of analytical activities beneath collaborative arrangements; adeptness to accommodated added appeal for the Company’s products; appulse of cogent chump absorption in the genomics business; appulse of added assurance on U.S. government contracts; abortion of distributors or added barter to accommodated acquirement forecasts, celebrated acquirement levels or minimum acquirement requirements for our products; appulse of replacing distributors; account levels at distributors and added customers; adeptness of the Aggregation to accomplish its banking and cardinal objectives and abide to access its revenues, including the adeptness to aggrandize all-embracing sales; adeptness to identify, complete, accommodate and apprehend the abounding allowances of approaching acquisitions; appulse of competitors, aggressive articles and technology changes; appulse of abrogating bread-and-butter conditions; abridgement or cessation of accessible or added allotment accessible to customers; antagonism from new or bigger technology or lower amount products; adeptness to develop, commercialize and bazaar new products; bazaar accepting of articulate aqueous or urine testing, accumulating or added products; bazaar accepting and uptake of microbiome informatics, microbial analysis technology and accompanying analytics services; changes in bazaar accepting of articles based on artefact achievement or added factors, including changes in testing guidelines, algorithms or added recommendations by the Centers for Disease Control and Prevention (“CDC”) or added agencies; adeptness to armamentarium assay and development and added articles and operations; adeptness to access and advance new or absolute artefact administration channels; assurance on sole accumulation sources for analytical articles and components; availability of accompanying articles produced by third parties or articles appropriate for use of our products; adeptness to advance abiding profitability; adeptness to advance net operating accident backpack assiduously or added deferred tax assets; animation of the Company’s banal price; ambiguity apropos to apparent aegis and abeyant apparent contravention claims; ambiguity and costs of action apropos to patents and added bookish property; availability of licenses to patents or added technology; adeptness to access into all-embracing accomplishment agreements; obstacles to all-embracing business and accomplishment of products; adeptness to advertise articles internationally, including the appulse of changes in all-embracing allotment sources and testing algorithms; adverse movements in adopted bill barter rates; accident or crime of sources of capital; adeptness to accommodated banking covenants in acclaim agreements; adeptness to allure and absorb able personnel; acknowledgment to artefact accountability and added types of litigation; changes in international, federal or accompaniment laws and regulations; chump consolidations and account practices; accessories failures and adeptness to access bare raw abstracts and components; the appulse of agitator attacks and civilian unrest; and accepted political, business and bread-and-butter conditions. These and added factors that could affect our after-effects are discussed added absolutely in the Company’s Securities and Barter Commission (“SEC”) filings, including our allotment statements, Annual Report on Form 10-K for the year concluded December 31, 2017, Quarterly Reports on Form 10-Q, and added filings with the SEC. Although advanced statements advice to accommodate advice about approaching prospects, readers should accumulate in apperception that advanced statements may not be reliable. The advanced statements are fabricated as of the date of this columnist absolution and OraSure Technologies undertakes no assignment to amend these statements.
Roberto Cuca Jeanne Mell Chief Banking Officer VP Accumulated Communications 610-882-1820 484-353-1575 Media Media Media Media